RxDoctor Payments Data

Fan Yang, MD

Internal Medicine · Flushing, NYNPI 1629340948

Payments from drug & device makers

$2,423in general payments, 2019–2025

Across 97 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$785
  • Exact Sciences$378
  • GSK$277
  • Phathom Pharmaceuticals, Inc.$244
  • Pfizer$161
  • Biohaven Pharmaceutical Holding Company Ltd.$102
  • plus $475 from 11 others

What the payments were for

  • Food & beverage$2,423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,423 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$27,891
Medicare patients
56
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl924$470,962
Diclofenac Epolamine578$268,764
JardianceEmpagliflozin195$186,657
FarxigaDapagliflozin Propanediol166$183,606
JanuviaSitagliptin Phosphate116$126,830
Diclofenac Sodium487$122,304
XareltoRivaroxaban68$66,720
EliquisApixaban79$63,629
CreonLipase/Protease/Amylase57$58,799
Lactulose25$52,942
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$51,267
VemlidyTenofovir Alafenamide35$51,251
TrulicityDulaglutide32$44,553
ProliaDenosumab20$34,306
ZenpepLipase/Protease/Amylase14$31,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Nexium, Symbicort$72$235,253297 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$22$220,132234 claims
AbbVieCreon, Linzess, Synthroid$35$87,168215 claims
PfizerEliquis$161$63,62979 claims
GSKTrelegy Ellipta$277$51,26776 claims
GileadVemlidy$15$51,25135 claims
Novo NordiskRybelsus, Ozempic$41$48,04042 claims
Lilly USA, LLCTrulicity$38$44,55332 claims
AmgenProlia$785$34,30620 claims
Esperion Therapeutics, Inc.Nexletol$54$27,74337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →